| [ Summary ] |
Hepatic arterial infusion chemotherapy has been recognized as a hopeful therapeutic strategy for liver metastasis treatment in periods of underpowered systemic chemotherapy. However, clinical trials have failed to show survival benefits of hepatic arterial infusion chemotherapy. Thus, in a period when systemic chemotherapy is showing significant advances, the use of hepatic arterial infusion chemotherapy should be limited to uncontrolled liver metastasis by systemic chemotherapy and to special situations where it can be used due to evidence obtained from clinical studies. On the other hand, the results of clinical studies must be considered based on a deep understanding of techniques for hepatic arterial infusion chemotherapy. If advances in systemic chemotherapy fail to control liver metastasis, a reappraisal of hepatic arterial infusion chemotherapy may be required. |